<< Back To Home

NEW THIS FRIDAY: SUPPORTING NEW VACCINE INTRODUCTION DECISIONS: LESSONS LEARNED FROM THE HIB INITIATIVE EXPERIENCE

Thursday, 18th of July 2013 Print
  • SUPPORTING NEW VACCINE INTRODUCTION DECISIONS: LESSONS LEARNED FROM THE HIB INITIATIVE EXPERIENCE

Vaccine. 2010 Oct 8;28(43):7123-9. Epub 2010 Jul 24.

Hajjeh RA et al.

Source

Division of Bacterial Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS C-25, Atlanta, GA 30333, USA. RHajjeh@cdc.gov, rfh5@cdc.gov

Abstract below; full text is available to journal subscribers

The introduction of Haemophilus influenzae type b (Hib) vaccine in developing countries has suffered from a long delay. Between 2005 and 2009, a surge in Hib vaccine adoption took place, particularly among GAVI-eligible countries. Several factors contributed to the increase in Hib vaccine adoption, including support provided by the Hib Initiative, a project funded by the GAVI Alliance in 2005 to accelerate evidence-informed decisions for use of Hib vaccine. This paper reviews the strategy adopted by the Hib Initiative and the lessons learned in the process, which provide a useful model to accelerate uptake of other new vaccines.

Copyright © 2010. Published by Elsevier Ltd. All rights reserved.

40987849